The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review
Rattachement africain : au, cl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Preclinical studies have shown a therapeutic role of the mechanistic/mammalian target of rapamycin complex 1 (mTORC1) inhibition with rapamycin and its analogues (rapalogues) on several age-related musculoskeletal disorders (MSKD). However, the applicability to humans of these findings is unknown. OBJECTIVE: To assess the efficacy of rapalogues on age-related MSKD in humans. METHODS: We conducted a systematic review according to the PRISMA guidelines. MEDLINE, EMBase, EMCare, and Cochrane Central Registry of Controlled Trials were searched for original studies examining the effects of rapalogues on outcomes linked to the age-related MSKD in humans. This review is registered in the PROSPERO database (University of New York; registration number CRD42020208167). RESULTS: Fourteen studies met the inclusion criteria and were analyzed. The effect of rapamycin and other rapalogues, including everolimus and temsirolimus, on bone, muscle and joints have been evaluated in humans; however, considerable variability concerning the subjects' age, inclusion criteria, and drug administration protocols was identified. In bone, the use of rapamycin is associated with a decrease in bone resorption markers dependent on osteoclastic activity. In muscle, rapamycin and rapalogues are associated with a reduction in muscle protein synthesis in response to exercise. In the context of rheumatoid arthritis, rapamycin and rapalogues have been associated with clinical improvement and a decrease in inflammatory activity. CONCLUSION: Although there are studies that have evaluated the effect of rapamycin and rapalogues on MSKD in humans, the evidence supporting its use is still incipient, and the clinical implication of these results on the development of osteoporosis, sarcopenia, or osteosarcopenia has not been studied, opening an interesting field for future research.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review
- Date Crossref
- 21/07/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Melbourne Australian Institute for Musculoskeletal Science (AIMSS) pays non établi dans la noticeUniversité ou école supérieure
-
Western Health pays non établi dans la noticeÉtablissement de santé
-
Australian Institute for Musculoskeletal Science pays non établi dans la noticeStructure de recherche
-
Hospital Clínico de la Universidad de Chile pays non établi dans la noticeÉtablissement de santé
-
Centro de Gerociencia pays non établi dans la noticeInstitution
-
Centro de Investigación Clínica Avanzada (CICA) pays non établi dans la noticeÉtablissement de santé
-
Clínica de Caídas Y Fracturas Sección de Geriatría pays non établi dans la noticeÉtablissement de santé
Australian Institute for Musculoskeletal Science (AIMSS) — The University of Melbourne, Western Health et Australian Institute for Musculoskeletal Science, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.